You deserve tomorrow.

Company History


  • Salisbury site acquired in 1983 by F H Faulding & Co Limited.
  • Development of delayed-release Doxycycline capsules (DORYX®).
  • Development of enteric coated aspirin (ASTRIX®).
  • WF Scammell Research Centre opened at Salisbury.


  • Development of taste-masking technology (CLEANTASTE®).
  • Development of sustained-release morphine (KADIAN® / KAPANOL®).
  • Metrics founded as a contract testing company in Greenville, North Carolina.


  • Development of improved bioavailability technology (SUBA™).
  • Development of pellet-in-a-tablet technology (DORYX®).
  • Development of LOZANOC®/TOLSURA® improved formulation of itraconazole.


  • Mayne Pharma acquires Metrics, Inc. - CDMO with niche generic product portfolio and pipeline.
  • Acquired Doryx® brand and related assets in the US from Actavis.
  • Mayne Pharma acquires US portfolio of products from Teva and Allergan in the US. 
  • Mayne Pharma acquires US foam dermatology products from GSK - FABIOR® and SORILUX®.
  • New solid oral dose manufacturing facility in Greenville, NC, USA opened.